Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

NCT02268136 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BIII 890 CL
DRUG: Placebo

Sponsor

Boehringer Ingelheim